HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts

AIDS Research and Human Retroviruses

Volumn 23, Issue 2, 2007, Pages 243-250

  Malizia, Andrea P ^a   Cotter, Eoin ^a   Chew, Nicholas ^a   Powderly, William G ^a   Doran, Peter P ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTIRETROVIRUS AGENT; CALCIUM; INDINAVIR; MESSENGER RNA; NELFINAVIR; RITONAVIR; SAQUINAVIR; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR RUNX2;

ARTICLE; BONE DENSITY; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE SILENCING; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROARRAY ANALYSIS; OSSIFICATION; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; SIDE EFFECT; UPREGULATION;

ALKALINE PHOSPHATASE; CALCIUM; CELL LINE; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; NELFINAVIR; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOBLASTS; RITONAVIR; SAQUINAVIR; TISSUE INHIBITOR OF METALLOPROTEINASE-3; UP-REGULATION;

EID: 33947283371     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0084     Document Type: Article

References (26)

1. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 counts of 200 per cubic millimetre or less. N Engl J Med 1997;337:725-733.
2. Palella FJ, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
3. Monini P, Sgadari C, Barillari G, and Ensoil B: HIV protease inhibitors: Antiretroviral agents with anti-inflamatory, anti-angiogenic and anti-tumour activity. J Antimicrob Chem 2003;51:207-211.
4. Mondy K and Tebas P: Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis 2003; 36:101-105.
5. Powderly WG: Long term exposure to lifelong therapies. J Acquir Immune Defic Syndr 2002;29:28-40.
6. Thomas J and Doherty SM: HIV infection-a risk factor for osteoporsis. J Acquir Immune Defic Syndr 2003;33:281-291.
7. Yelmokas McDermot A, Shevitz A, Knox T, et al.: Effect of highly active antiretroviral therapy on fat, lean and bone mass in HIV-seropositive men and women. Am J Clin Nutr 2001;74:679-686.
8. Tebas P, Powderly WG, Claxton S, et al.: Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000;14:63-67.
9. Mondy K, Yarasheski K, Powderly WG, et al.: Longditudinal evolution of bone mineral density and bone markers in human immunodeficiency virus infected individuals. Clin Infect Dis 2003;36: 182-190.
10. Amorosa V and Tebas P: Bone disease and HIV infection. Clin Infect Dis 2006;42:108-114.
11. Okada Y and Tanaka Y: Immune signals in the context of secondary osteoporosis. Histol Histopathol 2004;19:863-866.
12. Wang MW, Wei S, Teitelbaum SL, et al.: The HIV protease inhibitor indinavir uniquely inhibits bone formation. J Bone Miner Res 2001;16:S372.
13. Jain RG and Lenhard JM: Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem 2002;277:19247-19250.
14. Fakruddin JM and Laurence J: HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 2003;278:48251-48258.
15. Woessner JF: Matrix metalloproteinases and their inhibitors in connective tissue remodelling. FASEB J 1991;5(8);P2145.
16. Nascimbeni M, Lamotte C, Peytavin G, Farinotti R, and Clavel F: Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrob Agents Chemother 1999;43: 2629-2634.
17. Kieran NE, Doran PP, Connolly SB, et al.: Modification of the transcriptomic response to renal ischemia/reperfusion injury by lipoxin analog. Kidney Int 2003;64:480-492.
18. Bolstad BM, Irizarty RA, Astrand M, and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-193.
19. Irizarry RA, Bolstad BM, Collin F, et al.: Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
20. Eisen MB, Spellman PT, Brown PO, and Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-14868.
21. Dennis G Jr, Sherman BT, Hosack DA, et al.: DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 2003;4:P3.
22. Douglas AH, Glynn D Jr, Brad TS, Clifford Lane H, and Richard AL: Identifying biological themes within lists of genes with EASE. Genome Biol 2003;4:P4.
23. Cawston T: Matrix metalloproteinases and TIMPS: Properties and implications for the rheumatic disease. Mol Med Today 1998;4(3): P130.
24. Sepulveda JL, Gkretsi V, and Wu C: Assembly and signalling of adhesion complexes. Curr Top Dev Biol 2005;68;P183.
25. Fassina G, Ferrari N, Brigati C, et al.: Tissue inhibitors of metalloproteases: Regulation and biological activities. Clin Exp Metastasis 2000;18(2);P111.
26. Suzuki H, Nezaki Y, Kuno E, et al.: Functional roles of the tissue inhibitor of metalloproteinase 3 (TIMP-3) during ascorbate-induced differentiation of osteoblastic MC3T3-E1 cells. Biosci Biotechnol Biochem 2003;67(8):1737-1743.